Pfizer Wins Celebrex Patent Decision in Canadian Court, Launch of Generic Product by Novopharm Prohibited until 2014

    NEW YORK, April 30 /CNW/ - Pfizer Inc reported today that the Federal
Court of Appeal of Canada has reversed a lower court ruling that would have
permitted generic manufacturer Novopharm to launch a competitor product to
Celebrex. The appellate court issued an order prohibiting regulatory approval
of Novopharm's product in Canada until Celebrex's compound patent expires in
November 2014.

    "Today's ruling is an important one not only for Pfizer, but also for
patients in Canada and elsewhere," said Pfizer General Counsel Allen Waxman.
"Without appropriate protection of intellectual property, Pfizer and other
research-based pharmaceutical companies would not be able to make the
tremendous investments required to develop new, life-saving medicines that are
so critical to public health."

    Novopharm may seek to appeal the decision to the Supreme Court of Canada.

For further information:

For further information: Pfizer Inc Bryant Haskins, 212-733-8719

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890